(Q35192390)

7 August 2017

1 reference

title

Current bladder cancer tests: unnecessary or beneficial? (English)

1 reference

7 August 2017

1 reference

Michael A Simon

1

1 reference

PubMed ID

12900004

7 August 2017

Vinata B Lokeshwar

series ordinal

2

1 reference

PubMed ID

12900004

7 August 2017

Mark S Soloway

series ordinal

3

1 reference

7 August 2017

1 August 2003

1 reference

Critical Reviews in Oncology Hematology

7 August 2017

1 reference

7 August 2017

47

1 reference

7 August 2017

91-107

1 reference

7 August 2017

2

1 reference

Urine based markers of urological malignancy

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Superficial bladder cancer: progression and recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Biology and management of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

De novo muscle invasive bladder cancer: is there a change in trend?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Monitoring patients for bladder neoplasms: what can be expected of urinary cytology consultations in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Hematuria home screening: repeat testing results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

A community study of bladder cancer screening by the detection of occult urinary bleeding.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Home Screening for Hematuria: Results of a Multi-Clinic Study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Non-occupational risk factors for cancer of the lower urinary tract in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Tobacco, occupation and non-transitional-cell carcinoma of the bladder: an international case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Bladder cancer incidence in arylamine workers

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Cancer incidence and cause specific mortality among workers in two Norwegian aluminum reduction plants

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Cohort mortality study of 57,000 painters and union members: a 15 year update

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Noninvasive detection of bladder cancer with the BTA stat test

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Dipstick chemical urinalysis: an accurate cost-effective screening test

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Evaluation of hematuria in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Comparison of screening methods in the detection of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

The early detection and diagnosis of bladder cancer: a critical review of the options.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Usefulness of the BTA STAT Test for the diagnosis of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Utility of the BTA stat test kit for bladder cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Identification of a nuclear protein matrix.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

A fixed site of DNA replication in eucaryotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

NuMA is required for the proper completion of mitosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Utilization of nuclear matrix proteins for cancer diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Screening and monitoring for bladder cancer: refining the use of NMP22

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Urine cytology, tumour markers and bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Further study of fibrinogen degradation products in bladder cancer detection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Rapid detection of bladder cancer: a comparative study of point of care tests

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

MAUB is a new mucin antigen associated with bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Telomeres and their synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Structure and function of telomeres

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Telomere length regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Specific association of human telomerase activity with immortal cells and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Telomerase activity and cytokeratin 20 as markers for the detection and followup of transitional cell carcinoma: an unfulfilled promise

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Clinical evaluation of human telomerase catalytic subunit in bladder washings from patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Consecutive quantitative cytology in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

ELEVATED TISSUE EXPRESSION OF HYALURONIC ACID AND HYALURONIDASE VALIDATES THE HA-HAase URINE TEST FOR BLADDER CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

IAP family proteins--suppressors of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Tumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Urine detection of survivin and diagnosis of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Antigenic Deletion and Prognosis of Patients with Stage a Transitional Cell Bladder Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Comparison of BTA stat and NMP22 tests in the detection of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Follow-up in non-muscle invasive bladder cancer: facts and future

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer--a study of a randomly selected population of 2,400 men.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900074-X

7 January 2021

10.1016/S1040-8428(03)00074-X

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12900004